Selective antagonism of anticancer drugs for side-effect removal

Trends in Pharmacological Sciences

Volumn 30, Issue 8, 2009, Pages 403-410

  Fernández, Ariel ^a   Sessel, Sean ^a  

^a Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CD135 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; RAF PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SUNITINIB; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL FATE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HEART MUSCLE CELL; HUMAN; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOTOXINS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEOPLASMS; ORGAN SPECIFICITY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 67849087295     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.06.001     Document Type: Article

References (42)

1. Widakowich C., et al. Review: side effects of approved molecular targeted therapies in Solid Cancers. Oncologist 12 (2007) 1443-1455
2. Schmidinger M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26 (2008) 5204-5212
3. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6 (2006) 803-812
4. Verheul H.M., and Pinedo H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat. Rev. Cancer 7 (2007) 475-485
5. Force T., et al. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7 (2007) 332-344
6. Force T., and Kerkela R. Cardiotoxicity of the new cancer therapeutics - mechanisms of, and approaches to, the problem. Drug Discov. Today 13 (2008) 778-784
7. Kerkela R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12 (2006) 908-916
8. Chu T.F., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitnib. Lancet 370 (2007) 2011-2019
9. Fernández A., et al. Is there a case for selectively promiscuous anticancer drugs?. Drug Discov. Today 14 (2009) 1-5
10. Zhang X., et al. Turning promiscuous kinase inhibitors into safer drugs. Trends Biotechnol. 26 (2008) 295-301
11. Dancey J., and Sausville E.A. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2 (2003) 296-313
12. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
13. Fernández A., et al. An anticancer C-kit kinase inhibitor is re-engineered to make it more active and less cardiotoxic. J. Clin. Invest. 117 (2007) 4044-4054
14. Kitano H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 6 (2007) 202-209
15. Torchilin V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58 (2006) 1532-1555
16. Langer R. Drug delivery: drugs on target. Science 293 (2001) 58-59
17. Allen T.M., and Cullis P.R. Drug Delivery Systems: Entering the Mainstream. Science 303 (2004) 1818-1822
18. Deininger M., et al. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
19. Dancey J.E., and Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer drugs. Nat. Rev. Drug Discov. 5 (2006) 649-659
20. Keith C.T., et al. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4 (2005) 1-8
21. Zimmermann G.R., et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12 (2007) 34-42
22. Verweij J., et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analysis of EORTC-ISG-AGITG study 62005. Eur. J. Cancer 43 (2007) 974-978
23. Atallah E., et al. Congestive heart failure is a rare event in patients receiving imatinib. Blood 110 (2007) 1233-1237
24. Escudier B., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 125-134
25. O'Neill E., et al. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306 (2004) 2267-2270
26. Dhillon A.S., et al. MAP kinase signalling pathways in cancer. Oncogene 26 (2007) 3279-3290
27. Chen J., et al. Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics 23 (2007) 563-572
28. Faivre S., et al. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 6 (2007) 734-745
29. O'Neill E.E., et al. Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res. 65 (2005) 5485-5487
30. Kantarjian H., et al. Dasatinib. Nat. Rev. Drug Discov 5 (2006) 717-718
31. Lietha D., and Eck M.J. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One 3 (2008) e3800
32. Halder J., et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 67 (2007) 10976-10983
33. McLean G.W., et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat. Rev. Cancer 5 (2005) 505-515
34. Hirotani S., et al. Inhibition of glycogen synthase 3β during heart failure is protective. Circ. Res. 101 (2007) 1164-1174
35. Michael A., et al. Glycogen synthase kinase-3β regulates growth, calcium homeostasis, and diastolic functions in the heart. J. Biol. Chem. 279 (2004) 21383-21393
36. Cohen P., and Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3 (2004) 479-487
37. Karaman M.W., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008) 127-132
38. Crunkhorn S. Anticancer drugs: redesigning kinase inhibitors. Nat. Rev. Drug Discov. 7 (2008) 120-121
39. Fernández A. Keeping dry and crossing membranes. Nat. Biotechnol. 22 (2004) 1081-1084
40. Fernández A., and Scheraga H.A. Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 113-118
41. Fernández A., and Scott L.R. Adherence of packing defects in soluble proteins. Phys. Rev. Lett. 91 (2003) 018102-018105
42. Crespo A., and Fernández A. Kinase packing defects as drug targets. Drug Discov. Today 12 (2007) 917-923